{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:06:40Z","timestamp":1793153200259,"version":"4.5.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The ETAL-1 trial demonstrated that upfront allogeneic hematopoietic stem cell transplant (HSCT) improved disease-free survival, but not overall survival, when compared with consolidation chemotherapy followed by \u201cdelayed\u201d HSCT on relapse in patients with intermediate-risk acute myeloid leukemia (AML). However, the health-economic implications of upfront HSCT compared with delayed HSCT are unknown. We developed a partitioned survival analysis model using derived survival data, probabilities of salvage treatments, utilities, and costs from the ETAL-1 trial and published literature. The primary outcome was the incremental net monetary benefit (INMB) from the perspective of the United States and United Kingdom health care systems, at all accepted willingness-to-pay (WTP) thresholds: $50\u2009000 to $150\u2009000 per quality-adjusted life year (QALY), and \u00a320\u2009000 to \u00a330\u2009000 per QALY, respectively. The respective INMBs favored upfront HSCT, and were $497\u2009100 (95% confidence interval [CI], $259\u2009800-$719\u2009600) and \u00a3235\u2009600 (95% CI, \u00a3166\u2009800-\u00a3298\u2009500) at WTP thresholds of $150\u2009000 per QALY and \u00a330\u2009000 per QALY. Across deterministic sensitivity analyses, no model input changed the conclusion that upfront HSCT is the cost-effective strategy in either jurisdiction. Probabilistic sensitivity analysis showed that upfront HSCT was cost-effective in 100% of iterations, and was less costly and more effective (ie, \u201cdominant\u201d) in &amp;gt;90% of iterations in both health care systems. In conclusion, we conducted a partitioned survival analysis based on the ETAL-1 trial, and showed that proceeding to HSCT in first remission is the cost-effective strategy in the care of patients with intermediate-risk AML in both the United States and the United Kingdom, as compared with delayed HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016532","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T20:07:46Z","timestamp":1753733266000},"page":"5234-5246","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-8990","authenticated-orcid":false,"given":"Abdulrahman","family":"Alhajahjeh","sequence":"first","affiliation":[{"name":"1School of Medicine, Internal Medicine Department, The University of Jordan, Amman, Jordan"},{"name":"2Internal Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan K.","family":"Patel","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-778X","authenticated-orcid":false,"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Kewan","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-0579","authenticated-orcid":false,"given":"Jessica M.","family":"Stempel","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-2877","authenticated-orcid":false,"given":"Lourdes","family":"Mendez","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Seropian","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lohith","family":"Gowda","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"},{"name":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-4427","authenticated-orcid":false,"given":"George","family":"Goshua","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"},{"name":"6Center for Outcomes Research and Evaluation, Internal Medicine Department, Yale New Haven Hospital, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[{"name":"4Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"4","key":"2025102810114939300_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.hemonc.2017.05.021","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia: a review","volume":"10","author":"Kassim","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"8","key":"2025102810114939300_bib2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"2025102810114939300_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.blre.2017.07.002","article-title":"The who, how and why: allogeneic transplant for acute myeloid leukemia in patients older than 60 years","volume":"31","author":"Wall","year":"2017","journal-title":"Blood Rev"},{"issue":"12","key":"2025102810114939300_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025102810114939300_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025102810114939300_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","article-title":"Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial","volume":"9","author":"Bornh\u00e4user","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"2025102810114939300_bib7","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41409-023-02070-9","article-title":"Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT","volume":"58","author":"Chen","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2025102810114939300_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11912-021-01092-0","article-title":"Post-induction treatment for acute myeloid leukemia: something change?","volume":"23","author":"Jaramillo","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2025102810114939300_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2025102810114939300_bib10","unstructured":"Social Security Administration\n          . Period life table, 2022, as used in the 2025 trustees report. Accessed 26 February 2024. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html."},{"issue":"3","key":"2025102810114939300_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/cancers15030575","article-title":"At what point are long-term (&gt;5 years) survivors of APL safe? A study from the SEER database","volume":"15","author":"Yin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2025102810114939300_bib12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/cancers16071419","article-title":"Late relapse after allogeneic stem cell transplantation in patients treated for acute myeloid leukemia: relapse incidence, characteristics, role of conditioning regimen, and outcome","volume":"16","author":"Antier","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2025102810114939300_bib13","first-page":"849","article-title":"Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database","volume":"26","author":"Pandya","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"2025102810114939300_bib14","first-page":"637.e1","article-title":"Estimating the lifetime medical cost burden of an allogeneic hematopoietic cell transplantation patient","volume":"29","author":"Maziarz","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2025102810114939300_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12962-018-0153-4","article-title":"Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom","volume":"16","author":"Tremblay","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"issue":"12","key":"2025102810114939300_bib16","first-page":"1207.e1","article-title":"Healthcare resource utilization and associated costs in patients with chronic graft-versus-host disease post-allogeneic hematopoietic stem cell transplantation in England","volume":"30","author":"Avenoso","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2025102810114939300_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.bmt.1703641","article-title":"Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia","volume":"30","author":"van Agthoven","year":"2002","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2025102810114939300_bib18","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2022.281877","article-title":"Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndromes after a first transplantation","volume":"108","author":"Yerushalmi","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2025102810114939300_bib19","first-page":"362.e1","article-title":"Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC","volume":"29","author":"Kaphan","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"31","key":"2025102810114939300_bib20","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025102810114939300_bib21","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1182\/blood-2018-99-115420","article-title":"Donor lymphocyte infusion from G-CSF-primed, unmanipulated whole blood is safe and improves chimerism in HLA-matched and haploidentical transplantation","volume":"132","author":"G\u00f3mez-De Le\u00f3n","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2025102810114939300_bib22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/10428194.2022.2140288","article-title":"Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia","volume":"64","author":"Bewersdorf","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2025102810114939300_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/10428194.2024.2426073","article-title":"Cost-effectiveness of enasidenib versus conventional care for older patients with IDH2-mutant refractory\/relapsed AML","volume":"66","author":"Alhajahjeh","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2025102810114939300_bib24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1182\/blood.2021014401","article-title":"Cost-effectiveness of liposomal cytarabine\/daunorubicin in patients with newly diagnosed acute myeloid leukemia","volume":"139","author":"Bewersdorf","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025102810114939300_bib25","first-page":"5491","article-title":"Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation","volume":"28","author":"Yu","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6","key":"2025102810114939300_bib26","first-page":"504.e1","article-title":"Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis","volume":"27","author":"Bachier","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"2025102810114939300_bib27","doi-asserted-by":"crossref","first-page":"1320692","DOI":"10.3389\/fmed.2023.1320692","article-title":"Acute graft versus host disease 1976-2020: reduced incidence and predictive factors","volume":"10","author":"Di Francesco","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"2025102810114939300_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/ijh-2016-0001","article-title":"Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant","volume":"5","author":"Maziarz","year":"2016","journal-title":"Int J Hematol Oncol"},{"key":"2025102810114939300_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/CEOR.S153286","article-title":"Systematic review of health state utility values for acute myeloid leukemia","volume":"10","author":"Forsythe","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"2025102810114939300_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13696998.2019.1584108","article-title":"Health state utilities associated with treatment options for acute myeloid leukemia (AML)","volume":"22","author":"Matza","year":"2019","journal-title":"J Med Econ"},{"key":"2025102810114939300_bib31","unstructured":"Office for National Statistics\n          . Consumer price inflation, UK: August 2024. Accessed 14 December 2024. https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/bulletins\/consumerpriceinflation\/august2024."},{"key":"2025102810114939300_bib32","unstructured":"Macrotrends\n          . Pound dollar exchange rate - GBP USD (1971-2025). Accessed 14 December 2024. https:\/\/www.macrotrends.net\/2549\/pound-dollar-exchange-rate-historical-chart."},{"key":"2025102810114939300_bib33","unstructured":"Office for National Statistics\n          . CPI INDEX 06 : HEALTH 2015=100. Accessed 14 December 2024. https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/timeseries\/d7bz\/mm23."},{"key":"2025102810114939300_bib34","unstructured":"Bureau of Economic Analysis\n          . National data: national income and product accounts. Accessed 14 July 2024. https:\/\/apps.bea.gov\/iTable\/?reqid=19&step=2&isuri=1&categories=survey&_gl=1\u22175nywbb\u2217_ga\u2217MTA5MDkzNzQ4MC4xNzE4MDU4MTU4\u2217_ga_J4698JNNFT\u2217MTcxODA1ODE2OS4xLjEuMTcxODA1ODI3Mi4zNi4wLjA.#eyJhcHBpZCI6MTksInN0ZXBzIjpbMSwyLDNdLCJkYXRhIjpbWyJjYXRlZ29yaWVzIiwiU3VydmV5Il0sWyJOSVBBX1RhYmxlX0xpc3QiLCI3MyJdXX0=."},{"issue":"10","key":"2025102810114939300_bib35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"2025102810114939300_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/13696998.2018.1425209","article-title":"Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations","volume":"21","author":"Stein","year":"2018","journal-title":"J Med Econ"},{"issue":"11","key":"2025102810114939300_bib37","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1080\/10428194.2023.2235044","article-title":"Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States","volume":"64","author":"Muffly","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025102810114939300_bib38","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/13696998.2022.2091879","article-title":"The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States","volume":"25","author":"Tabah","year":"2022","journal-title":"J Med Econ"},{"issue":"1","key":"2025102810114939300_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17474086.2016.1112735","article-title":"Economic burden associated with acute myeloid leukemia treatment","volume":"9","author":"Zeidan","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2025102810114939300_bib40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"issue":"1","key":"2025102810114939300_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A health opportunity cost threshold for cost-effectiveness analysis in the United States","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"22","key":"2025102810114939300_bib42","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/bloodadvances.2021005472","article-title":"Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia","volume":"5","author":"Bewersdorf","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025102810114939300_bib43","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025102810114939300_bib44","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"2025102810114939300_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26757","article-title":"Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia","volume":"98","author":"Stahl","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2025102810114939300_bib46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"26","key":"2025102810114939300_bib47","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025102810114939300_bib48","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"38","key":"2025102810114939300_bib49","doi-asserted-by":"crossref","first-page":"63574","DOI":"10.18632\/oncotarget.18862","article-title":"Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"2025102810114939300_bib50","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2025102810114939300_bib51","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2025102810114939300_bib52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41409-018-0133-5","article-title":"Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years","volume":"53","author":"Debals-Gonthier","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2025102810114939300_bib53","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2025102810114939300_bib54","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1080\/10428194.2024.2344052","article-title":"Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia","volume":"65","author":"Bewersdorf","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025102810114939300_bib55","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2017.22","article-title":"Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5234\/2416887\/blooda_adv-2025-016532-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5234\/2416887\/blooda_adv-2025-016532-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:29:03Z","timestamp":1761661743000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5234\/546384\/Cost-effectiveness-of-upfront-vs-delayed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":55,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016532","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,16]]}}}